Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant melanoma.

J F Smyth

    Cancer Chemotherapy and Biological Response Modifiers
    |January 1, 1990
    PubMed
    Summary
    This summary is machine-generated.

    Early detection of thin malignant melanoma is crucial for favorable prognosis. Advanced melanoma management remains challenging, with limited benefit from cytotoxic drugs but promise from biological response modifiers.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The use of real-world data in cancer drug development.

    European journal of cancer (Oxford, England : 1990)·2018
    Same author

    Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies.

    Molecular oncology·2016
    Same author

    Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?

    Annals of oncology : official journal of the European Society for Medical Oncology·2013
    Same author

    Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy.

    Annals of oncology : official journal of the European Society for Medical Oncology·2011
    Same author

    Growth-control of human ovarian-carcinoma cells by insulin-like growth-factors.

    Oncology reports·2011
    Same author

    Clinically relevant fatigue in recurrence-free prostate cancer survivors.

    Annals of oncology : official journal of the European Society for Medical Oncology·2011
    Same journal

    Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    DNA vaccines for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Chemotherapy, cytokines, and biochemotherapy for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Current status of interferon-alpha in the treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    See all related articles

    Area of Science:

    • Oncology
    • Dermatology

    Background:

    • Advanced malignant melanoma presents significant management challenges.
    • Early detection of thin lesions is vital for improving patient prognosis.

    Purpose of the Study:

    • To review the current state of advanced malignant melanoma management.
    • To identify promising therapeutic avenues for refractory cases.

    Main Methods:

    • Review of existing literature on malignant melanoma treatment.
    • Analysis of data on early detection, regional perfusion, cytotoxic drugs, and biological response modifiers.

    Main Results:

    • Thin malignant melanoma lesions have a favorable prognosis, underscoring the importance of early detection.
    • Regional perfusion therapies show some encouraging results.

    Related Experiment Videos

  • Systemic metastases from malignant melanoma show minimal benefit from cytotoxic drugs.
  • Biological response modifiers offer genuine promise for influencing disease course.

    • Conclusions:

    • Continued difficulties persist in managing advanced malignant melanoma.
    • Early detection and educational programs are essential for improving outcomes.
    • Biological response modifiers represent a promising future direction for treating advanced and refractory malignant melanoma.